A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 51-57

  Emery, Paul ^a,b   Vencovský, Jirí ^c   Sylwestrzak, Anna ^d   Leszczynski, Piotr ^e   Porawska, Wieslawa ^f   Baranauskaite, Asta ^g   Tseluyko, Vira ^h   Zhdan, Vyacheslav M ⁱ   Stasiuk, Barbara ^j   Milasiene, Roma ^k   Rodriguez, Aaron Alejandro Barrera ^l   Cheong, Soo Yeon ^m   Ghil, Jeehoon ^m  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Chapel Allerton Hospital   (United Kingdom)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^d NZOZ Centrum Medyczne   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f Poznanski Osrodek Medyczny Novamed   (Poland)

^g LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^h KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

ⁱ MVSklifosovskyi Poltava Regional Clinical Hospital   (Ukraine)

^j Medicome Sp z oo   (Poland)

^k KLAIPEDA UNIVERSITY   (Lithuania)

^l Unidad de Atención Medica e Investigación en Salud UNAMIS   (Mexico)

^m Samsung Bioepis Co Ltd   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; DRUG ANTIBODY; ETANERCEPT; METHOTREXATE; ANTIBODY; ANTIRHEUMATIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BREAST CANCER; BREAST CARCINOMA; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE RASH; INJECTION SITE REACTION; LUNG CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PARALLEL DESIGN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; ETANERCEPT; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 84937604672     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207588     Document Type: Article

References (33)

1. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR: Fc) in rheumatoid arthritis. Ann Pharmacother 1997;31: 1335-8.
2. Goffe B, Cather JC. Etanercept: An overview. J Am Acad Dermatol 2003;49(2 Suppl): S105-11.
3. Fuchs BS, Hadi S. Use of etanercept in the treatment of psoriasis and psoriatic arthritis. Rev Recent Clin Trials 2006;1: 259-63.
4. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 2008;372: 375-82.
5. Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371: 1781-92.
6. Enbrel Summary of Product Characteristics. http: //www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000262/WC500027361.pdf (27 Feb 2015).
7. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. (EMEA/CHMP/BMWP/42832/2005). 22 February 2006. http: //www. ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003920.pdf (27 Feb 2015).
8. Kay J. Biosimilars: A regulatory perspective from America. Arthritis Res Ther 2011;13: 112.
9. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72: 322-8.
10. Lee YJ, Shin D, Kim Y, et al. A Phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects. EULAR Congress; 2015; Rome, Italy. European League Against Rheumatism. SAT0176
11. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340: 253-9.
12. Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: A double-blind comparison. Ann Rheum Dis 2006;65: 1357-62.
13. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50: 353-63.
14. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Non-inferiority clinical trials. http: //www.fda.gov/downloads/ Drugs/Guidances/UCM202140.pdf (27 Feb 2015).
15. Committee for Medicinal Products for Human Use (CHMP). Guideline on the choice of the non-inferiority margin. (EMEA/CPMP/EWP/2158/99). 27 July 2005. http: // www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003636.pdf (27 Feb 2015).
16. Reeve R, Pang L, Ferguson B, et al. Rheumatoid arthritis disease progression modeling. Ther Innov Regul Sci 2013;47: 641-50.
17. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363: 675-81.
18. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343: 1586-93.
19. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130: 478-86.
20. Kay JC, Chandrashekara A, Olakkengil S, et al. A phase 3, randomized, double-blind, active comparator study of the efficacy and safety of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses. EULAR Congress; 2014; Paris, France. OP0012.
21. Yoo DH, Piotrowski P, Ramiterre M, et al. A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis. EULAR Congress; 2012; Berlin, Germany. FRI0143.
22. Bae SC, Choe JS, Park JY, et al. A randomized, double-blind, phase 3 equivalence trial comparing the etanercept biosimilar, HD2013, with Enbrel®, in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA). EULAR Congress; 2014; Paris, France. OP0011.
23. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis. Jama 2012;308: 898-908.
24. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: A double-blind randomised 2-year study. Ann Rheum Dis 2009;68: 1146-52.
25. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25: 40-6.
26. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001;137: 893-9.
27. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46: 1443-50.
28. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011;100: 354-87.
29. Hermeling S, Crommelin DJ, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004;21: 897-903.
30. Rosenberg AS. Effects of protein aggregates: An immunologic perspective. Aaps j 2006;8: E501-7.
31. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Immunogenicity assessment for therapeutic protein products. http: //www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm338856.pdf (27 Feb 2015).
32. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71: 88-91.
33. Keystone E, Freundlich B, Schiff M, et al. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol 2009;36: 522-31.